Omeprazole treatment of children with peptic esophagitis refractory to raniditine therapy

Article Abstract:

Children with peptic esophagitis who do not respond to treatment with ranitidine may be successfully treated with omeprazole. A study of 153 children aged six to 18 years with chronic abdominal pain lasting more than three weeks found that 84% had peptic esophagitis, inflammation of the esophagus caused by the backup of stomach acids. Seventy percent of the children with peptic esophagitis were successfully treated with ranitidine hydrochloride. Omeprazole, a more powerful acid suppressing drug than ranitidine, was used to treat children that were not helped by ranitidine. Neither omeprazole nor ranitidine have been approved for use in children by the U.S. Food and Drug Administration, however, but both drugs might be safely used in children.

Complications and side effects, Abdominal pain, Ranitidine

---

Glycopyrrolate treatment of chronic drooling

Article Abstract:

Glycopyrrolate treatment appears to reduce severe chronic drooling, but may have unacceptable side effects. Researchers treated 40 patients with severe drooling due to neurologic disability with oral glycopyrrolate. Drooling decreased in 36 patients, 2 could not be assessed because medication was discontinued after an allergic reaction, and 2 showed no improvement. Nine patients discontinued treatment because of side effects, which included irritability, constipation, hives, urinary retention, and dry mouth. The effective dose varied widely. Twenty-six patients continued treatment because of the treatment's effectiveness after the study's conclusion.

Parasympatholytic agents, Parasympatholytics, Neuromuscular manifestations of general diseases

---

Omeprazole: Therapy of Choice in Intellectually Disabled Children

Article Abstract:

The anti-ulcer drug omeprazole appears to be effective in treating gastroesophageal reflux disease in intellectually disabled children. Researchers evaluated the drug's effect in 52 institutionalized intellectually disabled children. The drug was effective in 86%, no matter how serious their disease was during endoscopic examination. Seven patients relapsed when the dose was reduced, but became asymptomatic when the dose was increased. Endoscopy confirmed that esophageal inflammation was healed by the drug.

Care and treatment, Gastroesophageal reflux in children, Pediatric gastroesophageal reflux, Mentally disabled children

Similar abstracts:

• Abstracts: Cortical resection for children with epilepsy: perspectives in pediatrics. Esophageal motility in children with Hirschsprung's disease
• Abstracts: Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial
• Abstracts: New neuromuscular blocking drugs. Myocardial bridging in children with hypertrophic cardiomyopathy - a risk factor for sudden death
• Abstracts: Treatment of male infertility. The treatment of scabies with ivermectin. Endometrial resection for the treatment of menorrhagia
• Abstracts: The role of nurses in promoting testicular self-examination. For safety's sake

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.